Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
March 23 2021 - 6:08AM
Edgar (US Regulatory)
Filed
pursuant to Rule 433 of the
Securities
Act of 1933, as amended
Registration
No. 333-232067
Issuer
Free Writing Prospectus dated March 22, 2021
Relating
to Preliminary Prospectus Supplement dated March 22, 2021
Free
Writing Prospectus
Anixa Biosciences, Inc. (the “Company”) has filed a registration
statement (including a prospectus) with the Securities and Exchange Commission for the offering to which this communication relates.
Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement dated March
22, 2021 and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering.
The
information in this free writing prospectus supplements the preliminary prospectus supplement dated March 22, 2021, as follows:
Anixa
Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
SAN
JOSE, Calif., March 22, 2021 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa”
or the “Company”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases,
today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and
purchase on a firm commitment basis 4,285,715 shares of common stock of the Company at a public offering price of $5.25 per share,
less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an
additional 642,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering
is expected to close on or about March 25, 2021, subject to satisfaction of customary closing conditions.
H.C.
Wainwright & Co. is acting as the sole book-running manager for the offering.
The
gross proceeds of the offering are expected to be approximately $22.5 million, prior to deducting underwriting discounts and commissions
and estimated offering expenses payable by the Company and excluding the exercise of the underwriter’s option to purchase
additional shares. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but
not limited to, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical
technologies, investing in or acquiring companies that are synergistic with or complementary to its technologies, and licensing
activities related to current and future product candidates and working capital.
The
shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-232067)
that was filed with the U.S. Securities and Exchange Commission (“SEC”) on June 11, 2019 and declared effective on
June 21, 2019. The shares of common stock may be offered only by means of a prospectus supplement forming a part of the effective
registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with
the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and, upon filing, may be obtained on the SEC’s website at http://www.sec.gov
or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by email at placements@hcwco.com or
by phone at (212) 856-5711.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About
Anixa
Anixa
Biosciences, Inc. is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious
disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein
function. The company’s vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast
cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus
on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa’s therapeutic
and vaccine programs are currently in the research or pre-clinical stage of development. Anixa continually examines emerging technologies
in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking
Statements
This
press release may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of
1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise
include the words “believes,” “expects,” “anticipates,” “estimates,” “projects,”
“intends,” “should,” “seeks,” “future,” “continue,” or the negative
of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events
are based upon information available to Anixa as of today’s date and are not guarantees of the future performance of the
company, and actual results may vary materially from the results and expectations discussed. Some of the risks and other factors
that could cause the results to differ materially from those expressed in the forward-looking information include, but are not
limited to: market and other conditions, the completion of the public offering, the satisfaction of customary closing conditions
related to the public offering and the intended use of net proceeds from the public offering. Additional information concerning
these and other risks is contained in Anixa’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q,
recent Current Reports on Form 8-K and other SEC filings. All subsequent written and oral forward-looking statements concerning
Anixa, or other matters and attributable to Anixa or any person acting on its behalf are expressly qualified in their entirety
by the cautionary statements above. Anixa does not undertake any obligation to publicly update any of these forward-looking statements
to reflect events or circumstances that may arise after the date hereof, except as required by law.
Anixa
Investor contact:
Mike
Catelani
mcatelani@anixa.com
408-708-9808
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Apr 2023 to Apr 2024